AEON Biopharma Inc (AMEX:AEON)’s traded shares stood at 4.92 million during the last session, with the company’s beta value hitting 0.24. At the close of trading, the stock’s price was $0.85, to imply a decrease of -40.14% or -$0.57 in intraday trading. The AEON share’s 52-week high remains $1236.24, putting it -145340.0% down since that peak but still an impressive -60.0% since price per share fell to its 52-week low of $1.36.

Analysts have given a consensus recommendation of Buy for AEON Biopharma Inc (AEON), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give AEON a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.

AEON Biopharma Inc (AMEX:AEON) trade information

After registering a -40.14% downside in the last session, AEON Biopharma Inc (AEON) has traded red over the past five days. The 5-day price performance for the stock is -89.73%, and -90.87% over 30 days. With these gigs, the year-to-date price performance is -97.81%.

AEON Dividends

AEON Biopharma Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the AEON Biopharma Inc (AEON) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 5.76 shares. This is just over 0.00% of the total shares, with a market valuation of $4898.0. Data from the same date shows that the other fund manager holds a little less at 4.46, or 0.00% of the shares, all valued at about 3788.0.